IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Occipital Nerve Stimulation to Treat Chronic Headaches
This study has been completed.
Sponsor:
Boston Scientific Corporation
Information provided by:
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00205894
First received: September 13, 2005
Last updated: September 4, 2008
Last verified: August 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and efficacy of a implantable device, called the bion(R), in the treatment of chronic headache. The bion microstimulator is placed underneath the skin next to the greater occipital nerve. The bion microstimulator then stimulates the nerve by generating small amounts of electrical current.
| Condition | Intervention | Phase |
|---|---|---|
| Headache Disorders | Device: bion microstimulator | Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Multicenter Feasibility Study of the Bion for Occipital Nerve Stimulation for Treatment of Chronic Headaches |
Resource links provided by NLM:
Further study details as provided by Boston Scientific Corporation:
Primary Outcome Measures:
- The primary safety measure is the incidence of major complications, defined as device or procedure related major adverse events that require medical and surgical intervention.
- The primary efficacy measure is a significant reduction in the frequency, severity or duration of the headaches from the preoperative to the three-month follow-up period.
| Enrollment: | 20 |
| Study Start Date: | January 2004 |
| Study Completion Date: | September 2007 |
| Primary Completion Date: | October 2006 (Final data collection date for primary outcome measure) |
Chronic migraine and chronic cluster headaches are among the most disabling medical illnesses, inflicting severe functional impairment. These headache subtypes are particularly resistant to current treatment modalities, with the majority of chronic migraine patients continuing to experience frequent or near-daily headaches despite aggressive, multidisciplinary, and multimodal therapy. The refractory nature of these illnesses and the level of devastation they inflict on the lives of their victims has motivated the pursuit of novel treatment approaches.
Direct stimulation of the greater occipital nerve has been shown to alleviate the symptoms of chronic migraine and chronic cluster headaches in a small number of patients.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Be diagnosed with chronic migraine, probable chronic migraine, and/or chronic cluster headache according to the 2004 IHS Classification Criteria (2nd ed.) or be diagnosed with migraine with or without aura
- Be 18 years of age or older
- Be willing and able to follow all study-related procedures during the course of the study;
- Have exhibited refractoriness to two acute medication regimens and two prophylactic medications from two separate preventative classes.
Exclusion Criteria:
- Have received a botulinum toxin (botox) injection for treatment of headache within the last 90 days;
- Have previously undergone destructive ganglionectomy affecting C2/C3 occipital and/or trigeminal distribution or have an occipital blockade currently in effect;
- Have had a previous surgery in the intended implant area;
- Have Arnold-Chiari malformation;
- Have participated within the last 30 days or plan to participate within the next 4 months in a device or drug trial;
- Be pregnant or planning on becoming pregnant during the study period;
- Have an implanted electrical device (e.g., pacemaker, spinal cord stimulator) that may interfere with this therapy; and
- Currently require, or be likely to require, MRI or diathermy.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00205894
Please refer to this study by its ClinicalTrials.gov identifier: NCT00205894
Locations
| United States, Arizona | |
| Mayo Clinic | |
| Scottsdale, Arizona, United States, 85259 | |
| United States, Michigan | |
| Michigan Head Pain & Neurological Institute | |
| Ann Arbor, Michigan, United States, 48104 | |
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
| Principal Investigator: | David Dodick, MD | Mayo Clinic |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Pam Phongpharnich, Sr. Clinical Research Associate, Boston Scientific |
| ClinicalTrials.gov Identifier: | NCT00205894 History of Changes |
| Other Study ID Numbers: |
CR-B-003 |
| Study First Received: | September 13, 2005 |
| Last Updated: | September 4, 2008 |
Keywords provided by Boston Scientific Corporation:
|
Headache Chronic headache Migraine Pain Cluster headache |
Additional relevant MeSH terms:
|
Headache Headache Disorders Pain Neurologic Manifestations |
Nervous System Diseases Signs and Symptoms Brain Diseases Central Nervous System Diseases |
ClinicalTrials.gov processed this record on July 18, 2017